700 patients110,866 observations180 daysLIVE

Patient P-02530

Synthetic patientMETA-24 · Day 170 · 45–54 · F · baseline S07Steering view · 3DOpen companion preview
Therapy response
Favorable
Tolerance
Stable
GI state
Improving
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
55%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S07
  2. Day 109 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 109.

Primary contributors, last 14 days
  • GI instability-14
  • Nutritional resilience+3
  • Toxicity+3
  • Inflammatory activity-2

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    68%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 89% showed improvement
    • median effect visible after 8 days

    Daily trackers

    Molecule settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    Active minutes
    Wearable
    53 min
    stable · +1.5 vs previous 14 d
    Sleep duration
    Wearable
    6.9 h
    stable · +0.1 vs previous 14 d
    Energy level
    Daily log
    2.9/10
    improving · +0.1 vs previous 14 d
    Steps
    Wearable
    4,886
    stable · -52 vs previous 14 d
    GI burden
    Companion
    54.3/100
    improving · -5.0 vs previous 14 d
    Adherence
    Companion
    70.1 %
    worsening · -5.0 vs previous 14 d
    Sleep quality
    Wearable
    33.5/100
    improving · +3.8 vs previous 14 d
    Glucose, CGM daily mean
    CGM
    147 mg/dL
    stable · -2.4 vs previous 14 d
    This trajectory is doing well — what to keep, what to watch
    Steering view →

    Heading towards restoration · 46 from the failing basin, 52 from restoration.

    Good elements to keep
    • Protein (supports)
      perturbation · steering +9.1
    • Insoluble fibre (supports)
      perturbation · steering +5.4
    • Daily walks resumed
      perturbation · steering +3.3
    • Protein
      supporter · GI -5.2 next day
    • Insoluble fibre
      supporter · GI -3.1 next day
    Main detractors to watch
    • Low butyrate capacity
      hidden · steering -17.5
    • Bacteroides fragilis elevated
      hidden · steering -7.4
    • Dietary fat load
      perturbation · steering -7.4
    • Antibiotic course
      perturbation · steering -4.7
    • Dietary fat load
      detractor · GI +3.8 next day
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Protein
      -5.2supporter · 95%
    • Dietary fat load
      +3.8detractor · 95%
    • Insoluble fibre
      -3.1supporter · 66%
    • Caffeine
      -0.7no signal · 15%
    • Ultra-processed food
      +0.7no signal · 17%
    • Histamine load
      +0.5no signal · 15%
    • Simple carbohydrates
      -0.2no signal · 15%
    • Alcohol
      +0.2no signal · 15%

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Butyrate / short-chain fatty acid production 80
      • MicrobiomeButyrate capacity 33/100
      • MicrobiomeF. prausnitzii depleted
      • Daily logFibre intake low in recent food logs
    • Inflammatory signalling 60
      • MicrobiomeBacteroides fragilis expansion
      • BloodInflammatory load index 58
      • WearableHRV 24 ms, trending down
    • Autonomic recovery 25
      • WearableResting HR 76 bpm
    • Mucosal barrier integrity 20
      • Daily logGI symptom score 54 and rising
    • Drug metabolism and exposure 20
      • BloodToxicity index 58
    DNA
    Fictional pharmacogenomic panel
    • CYP2D6 Intermediate metabolizer
      Expected exposure
    • GLP1R rs6923761 A
      Altered receptor sensitivity
    • MTHFR C677T
      Reduced folate turnover
    Microbiome
    Shannon diversity 3.2 · butyrate capacity 33/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisHigh
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    23 ms
    Sleep
    6.5 h
    Steps
    6,180
    Resting HR
    79 bpm
    Daily log: GI score 54, nutritional resilience 36, adherence 70.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Eat slowly and stop at comfortable fullness — smaller volume, more often
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • A 15-minute walk after lunch
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the dose at the same time relative to your evening meal
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0226557%S07GI-04no change67
    P-0233453%S04GI-04improved66
    P-0243349%S07GI-04improved61
    P-0208448%S11GI-04no change58
    P-0259148%S1368
    P-0213646%S1063
    P-0263146%S1758
    P-0200943%S08CR-01improved64
    P-0202943%S1856
    P-0204643%S1055
    P-0205443%S01CR-01improved57
    P-0259543%S0253